Positive results for Feraccru® in AEGIS-H2H non-inferiority study

4 Mar 2019

Shield Therapeutics plc, announces positive results from the AEGIS-H2H clinical trial which compared Feraccru® (ferric maltol), a novel oral iron replacement therapy, to Ferinject® (ferric carboxymaltose (FCM)), the market-leading intravenously delivered iron replacement therapy. For more details click here.

Back to news